The FDA has given the green light to Eli Lilly’s Onswik, a once-weekly basal insulin injection designed for adults managing type 2 diabetes. This approval marks a significant step forward, providing an alternative to the traditional daily long-acting insulin shots, potentially improving treatment adherence and patient convenience.
The American Customer Satisfaction Index read 76.1 in August 2026, the same score it held in 2015, so United States customer expectations have held flat for eleven years while complaints hit records and the variable that actually moved was tolerance.
Read More
TLDR: Regulated-industry marketers who build neuromarketing capabilities at pre-launch stage convert compliance...
Read More